Preclinical AML studies showed palbociclib plus venetoclax produced stronger, more durable anti‑leukemia activity than venetoclax alone and may overcome resistance.

Targeting SUMOylation in glioblastoma opens new avenue for therapeutic interventions and biomarker discovery Glioblastoma, a ...

A multi-omics study identifies causal genes and biological subtypes of long COVID, revealing new therapeutic targets for ...

Researchers have identified chromosomal instability in circulating tumour cells as a prognostic and predictive biomarker in ...

A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people ...

Research shows hair follicle aging begins in your 30s, driven by inflammation-linked gene activity detectable years before ...

Hair loss and graying, the earliest visible hallmarks of skin aging, result from the functional decline of hair follicle stem ...

A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people with acute myeloid leukemia overcome resistance to one of the most common ...

Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During ...

A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people ...

The field of sepsis research has advanced significantly in recent years, particularly regarding the interplay between immune responses and multiple forms of ...

As people live longer, the gut quietly accumulates damage that can tip the balance between healthy tissue renewal and chronic ...